English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/2711
Compartir / Impacto:
Estadísticas
Add this article to your Mendeley library MendeleyBASE
Ver citas en Google académico
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar otros formatos: Exportar EndNote (RIS)Exportar EndNote (RIS)Exportar EndNote (RIS)
Título : Therapeutic compound against Leishmania infection and to the use thereof
Compuesto terapéutico frente a la infección por Leishmania y su uso.
Autor : Corbí, Angel L. ; Colmenares, María ; Rivas, Luis ; Relloso, Miguel
Fecha de publicación : 31-dic-2003
Citación : Internatonional Publication Number: WO 2004/000352 A1
Resumen: The invention relates to a therapeutic compound against Leishmania infection and to the use thereof. Said invention has for the first time demonstrated the role of the DC-SIGN (Dendritic cell-specific ICAM 3 grabbing non-integrin) receptor, which is present on the surface of dendritic cells, in the process of binding the Leishmania parasite to human eukaryotic cells, among others, dendritic cells, macrophages and cells derived from monocytes. The invention relates to a novel therapeutic compound against Leishmania infection, which can block or cancel the binding of the infectious forms of the Leishmania parasite to the DC-SIGN receptor which is present in eukaryotic cells, among others, human dendritic cells and certain macrophage populations, and the subsequent inhibition of the internalisation of the parasite.
Descripción : Filing Date: 2003-06-20.--Priority Data: ES P200201436 (2002-06-21)
URI : http://hdl.handle.net/10261/2711
Aparece en las colecciones: (CIB) Patentes
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
WO_2004_000352_A1[1].pdf1,92 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.